Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

v3.22.1
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS
 3 Months Ended
Mar. 31, 2022
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

NOTE 18. REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

Disaggregation of Net Revenues

The Company’s net product revenues are summarized as follows:

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended March 31, 

($ in thousands)

    

2022

    

2021

Qbrexa®

​

$

7,376

​

$

—

Accutane®

​

 

4,907

​

 

196

Amzeeq®

​

​

3,466

​

​

—

Targadox®

​

​

2,634

​

​

7,199

Ximino®

​

​

967

​

​

2,100

Zilxi®

​

​

741

​

​

—

Exelderm®

​

 

704

​

 

1,217

Other branded revenue

​

 

1

​

 

7

Total product revenues

​

$

20,796

​

$

10,719

​

The above table includes the authorized generic product within the line items for Targadox®, Ximino® and Exelderm®.
​

Significant Customers

For the three-month periods ended March 31, 2022 and 2021, there were no customers that accounted for more than 10% of the Company’s total gross product revenue.

At March 31, 2022, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 15% and 10%. At December 31, 2021, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 16% and 13%.

Other Revenue

Other revenue for the three-month period ended March 31, 2022 reflects a net $2.5 million milestone payment from the Company's exclusive out-licensing partner in Japan, Maruho Co., Ltd (“Maruho”). In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5% (Japanese equivalent to U.S. FDA approved QBREXZA®), for the treatment of primary axillary hyperhidrosis, triggering the net payment. The net payment reflects a milestone payment of $10.0 million to the Company from Maruho, offset by a $7.5 million payment to Dermira, Inc., pursuant to the terms of the Asset Purchase Agreement between the Company and Dermira.